Corvus Pharmaceuticals, Inc. (CRVS) company profile
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
About Corvus Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted therapies for immune-mediated diseases, inflammatory conditions, and cancers. Its research targets proteins critical to immune cell differentiation and function. The pipeline features soquelitinib, an oral covalent ITK inhibitor being evaluated in clinical studies for peripheral T-cell lymphomas and atopic dermatitis. Additional clinical-stage assets include ciforadenant, an adenosine A2A receptor antagonist under investigation for metastatic renal cell carcinoma, and mupadolimab, a B-cell-activating monoclonal antibody directed against CD73. Because the company does not operate commercial products, its programs address patient populations in specialized clinical trials.
The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers to produce, fill, label, package, and distribute its investigational therapies. Its operations and intellectual property span international jurisdictions, maintaining patent protections and applications across the United States, Europe, Canada, Japan, South Korea, Australia, and China. The provided text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Corvus Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Corvus Pharmaceuticals, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 901 Gateway Blvd, Third Floor 94080
- Phone
- (650) 900-4520
- Website
- corvuspharma.com
- Employees
- 37, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopersLLP, San Jose, California
Stock & identifiers
- Ticker
- CRVS
- Exchange
- Nasdaq
- IPO date
- Mar 24, 2016
- Shares outstanding
- 84M, Aug 6, 2026
- Public float
- $251.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1626971
- CUSIP
- 221015100
- ISIN
- US2210151005
- FIGI
- BBG009F0TGH8
- Share class FIGI
- BBG009F0TGJ6
- LEI
- 549300I3AVJ8F75NCX65
- EIN
- 46-4670809
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Richard A. Miller Md | President and CEO, Director | 2,331,742 |
| Jeffrey Arcara | Chief Business Officer | 4,500 |
| Leiv Lea | Chief Financial Officer | 282,444 |
| William Benton Jones | See Remarks | 173,130 |
| den Broek Richard van | Director | 160,000 |
| David Scott Moore | Director | 21,700 |
| Linda Grais | Director | 10,000 |
| Peter A. Thompson | Director | 8,729,091 |
| Ian T. Clark | Director | – |
| Andrew C. Chan | Director | – |
| Capital GP V. LLC OrbiMed | Director | 6,943,654 |
| Advisors Llc Orbimed | Director | 8,341,338 |
| Scott W. Morrison | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.03M | $7.33M | $3.18M | $906 | – |
| FY2024 | $3.07M | $7.47M | $1.59M | $629 | – |
| FY2023 | $1.32M | $2.57M | $638.51K | $207 | – |
| FY2022 | $524.24K | -$326.17K | $476.70K | $35 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Richard A. Miller President and Chief Executive Officer | $36.57K | $6.99M | $6.00K | $7.03M | +129% |
| Leiv Lea Chief Financial Officer | $405.95K | $2.80M | $6.00K | $3.21M | +99% |
| William B. Jones Senior Vice President, Pharmaceutical Development | $360.12K | $2.80M | $6.00K | $3.16M | +101% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 24, 2016
- Offer price
- $15.00
- Securities offered
- 4,700,000
- Gross proceeds
- $70.50M
- Exchange
- Nasdaq
- First trading day
- Mar 23, 2016
- First-day close
- $14.25-5.0%
- Lock-up ends (est.)
- Sep 19, 2016
“The initial public offering price of our common stock is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 37 total employees, all of whom were full-time and 29 of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 28, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 5, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 24, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 16, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?